Development of Molecular Pharmacodynamic Assays for Targeted Therapies

Information

  • Research Project
  • 7945131
  • ApplicationId
    7945131
  • Core Project Number
    261200900069C-0-0-1
  • Full Project Number
    261200900069C-0-0-1
  • Serial Number
    0
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/2009 - 15 years ago
  • Project End Date
    3/31/2010 - 14 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2009
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

Development of Molecular Pharmacodynamic Assays for Targeted Therapies

During the Phase I portion of this contract Singulex will develop Erenna assays for human EGFR, MMP[unreadable]2, TIMP2, and MMp[unreadable]2rr1MP-2 complex. We will carry out preliminary validation of these assays and demonstrate feasibility of these assays for measuring the target analytes in human tissues.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    N43
  • Administering IC
    CA
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    149760
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:149760\
  • Funding Mechanism
    Contracts, Extramural
  • Study Section
  • Study Section Name
  • Organization Name
    SINGULEX, INC.
  • Organization Department
  • Organization DUNS
    946338688
  • Organization City
    ALAMEDA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94502
  • Organization District
    UNITED STATES